Research programme: esterase-sensitive motif targeted therapeutics - Macrophage Pharma

Drug Profile

Research programme: esterase-sensitive motif targeted therapeutics - Macrophage Pharma

Alternative Names: CHR 6155; ESM™-p38 MAPK inhibitor; MPL 5821

Latest Information Update: 21 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; GlaxoSmithKline
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA inhibitors; Histone deacetylase inhibitors; HSP90 heat-shock protein inhibitors; Macrophage colony stimulating factor inhibitors; P38 mitogen-activated protein kinase inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Inflammation

Most Recent Events

  • 09 Nov 2017 Aquila BioMedical enters into an agreement with Macrophage Pharma to support preclinical immuno-oncology programmes
  • 11 May 2017 Macrophage Pharma plans a clinical trial for Cancer in 2019
  • 20 Jan 2017 No development reported - Preclinical for Inflammation in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top